Xintela AB (DE:1XT)
FRANKFURT:1XT
Want to see DE:1XT full AI Analyst Report?
1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
€19.64M
Enterprise Value€158.96M
Total Cash (Recent Filing)€23.21M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding861,266,850
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)-37.15
Price to Sales (P/S)85.84
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€1.09M
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformXintela's patented ITGA10 platform is a durable competitive asset that supports multiple programs in regenerative medicine and oncology. A platform model enables out-licensing, co-development, and portfolio diversification, lowering single-product risk and creating multiple long-term commercialization pathways.
Low Financial LeverageZero reported debt reduces fixed financing obligations and refinancing pressure, improving strategic flexibility for a development-stage biotech. This structural balance-sheet feature helps preserve runway options and partner-negotiation leverage despite ongoing cash needs.
Positive Gross ProfitReported positive gross profit in recent years suggests underlying product or program economics that can scale into sustainable margins once fixed R&D and SG&A are absorbed. This supports a credible path to improving operating profitability as revenues grow or partners assume development costs.
Bears Say
Persistent Cash BurnSustained large negative operating cash flow indicates continuous external financing needs. Over 2–6 months this structural cash burn raises dilution and financing-risk concerns, can delay programs if funding tightens, and constrains the company's ability to self-fund development or scale operations.
Negative Shareholders' EquityA sustained negative equity position weakens balance-sheet resilience and limits financing options. It can impair the firm's ability to raise capital on favorable terms, deter some partners or investors, and reduces the financial buffer against continued losses and unexpected setbacks.
Small, Volatile Revenue BaseVolatile and minimal revenue relative to high operating costs means the company lacks internal cash generation to fund development. This structural weakness increases dependency on partners and external funding, making long-term planning, scaling and margin improvement uncertain.
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €19.64M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Aug 28, 2026 which is in 97 days.
How were Xintela AB’s earnings last quarter?
Currently, no data Available
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xintela AB have?
Xintela AB has 861,266,850 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―